OVERVIEW OF PSORIATIC ARTHRITIS: CLINICAL CONSIDERATIONS FOR HEALTHCARE PROFESSIONALS JAMIE L. MCCONAHA, PHARMD, NCTTP, BCACP, CDE
|
|
- Verity Holmes
- 5 years ago
- Views:
Transcription
1 OVERVIEW OF PSORIATIC ARTHRITIS: CLINICAL CONSIDERATIONS FOR HEALTHCARE PROFESSIONALS JAMIE L. MCCONAHA, PHARMD, NCTTP, BCACP, CDE
2 FACULTY DISCLOSURES I have no conflicts of interest to disclose. I do not intend to discuss non-fda approved drugs or investigational use of any product/device.
3 OBJECTIVES Describe the epidemiology and pathophysiology of PsA List the clinical features and manifestations of PsA that may aid in diagnosis and assessment of disease severity Describe screening tools for patients suspected of having PsA Discuss the importance of early detection of PsA and methods and tests used to diagnose the disease Review treatment and management strategies for patients with PsA
4 PSORIATIC ARTHRITIS (PSA)
5 WHAT IS PSORIATIC ARTHRITIS? Chronic, progressive, inflammatory arthritis Considered a type of spondyloarthropathy Swelling, stiffness, and pain in and around the joints, as well as overall fatigue Early recognition, diagnosis and treatment is crucial to prevent permanent damage
6 INCIDENCE Prevalence in patients with psoriasis ranges between 6-42% Affects approximately 1% of the general population Estimates vary due to delayed or missed diagnoses Psoriatic arthritis. National Psoriasis Foundation. Available at: Gelfand JM, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs
7 EPIDEMIOLOGY Affects both men and women equally Usually occurs between years, but can affect any age Relationship to psoriasis (skin): 85% of patients present with skin psoriasis first 10-37% have skin and joint disease simultaneously 6-18% have arthritis preceding psoriasis Liu JT, Yeh, HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop Sep 18; 5(4):
8 INCIDENCE AND PREVALENCE COMPARISON Country Incidence (1/100000) Prevalence China NA 0.02% Japan % Greece % France NA 0.19% Italy NA 0.42% Germany NA 0.29% Finland 23.1 NA United States % Mexico NA 0.02% Liu JT, Yeh, HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop Sep 18; 5(4):
9 PATHOPHYSIOLOGY Exact cause is unknown Complex interplay of genetic, environmental, and immunologic factors Genetics: strong familial association Environmental: may trigger immune response (viruses or physical trauma) Immunologic: activated T cells in joint tissue; TNF-α guides inflammatory process Husni ME. Psoriatic arthritis. Cleveland Clinic. Oct FitzGerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009; 11(1): 214.
10 COMORBID CONDITIONS Psoriasis and psoriatic arthritis comorbidities: Cancer Cardiovascular disease Crohn s Disease Depression Diabetes Metabolic syndrome Obesity Osteoporosis Uveitis Liver disease Treatment of the underlying condition (psoriasis/arthritis) often alleviates comorbid condition symptoms or reduces risk National Psoriasis Foundation. Comorbidities associated with psoriatic arthritis.
11 SIGNS AND SYMPTOMS Painful, swollen joints Stiffness Dactylitis (sausage-like swelling) Enthesitis (tendon or ligament pain) Nail and skin changes Fatigue
12 SIGNS AND SYMPTOMS DIP involvement (39%) Back Involvement (40%) Nail psoriasis (67%) Dactylitis (48%) Enthesopathy (38%)
13 SIGNS AND SYMPTOMS Many patients experience nonspecific musculoskeletal symptoms before diagnosis In a 2017 study by Eder et al, the following preclinical symptoms predicted the development of psoriatic arthritis: Arthralgia in women (hazard ratio [HR] 2.59, P=0.02) Heel pain (HR 4.18, P=0.02) High fatigue score (HR 2.36, P=0.007) High stiffness score (HR 2.03, P=0.045) Eder L, et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017; Mar. 69(3):
14 PSORIATIC ARTHRITIS VS RHEUMATOID ARTHRITIS PsA Sex Distribution Males = Females Females > Males Symptoms Swelling, pain and stiffness RA Swelling, pain and stiffness Joint Involvement Ray pattern distribution Symmetrical distribution Extra-Articular Manifestations Rheumatoid nodules absent Nail involvement ~20 nail pits Absent Rheumatoid nodules present Blood Tests Seronegative Seropositive Gladman DD, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64(Suppl II).
15 DIAGNOSIS Imaging X-Rays: Pinpoint changes in the affected joints CT or MRI: Identify changes in tendons or ligaments or otherwise more detailed examination of joints Laboratory Rheumatoid Factor (RF): Usually absent in psoriatic arthritis Synovial Fluid: Aspiration and examination of synovial fluid of an affected joint revealing uric acid crystals to rule out gout There is no single test to confirm a psoriatic arthritis diagnosis.
16 CLASSIFICATION OF PSORIATIC ARTHRITIS Moll and Wright Classification Criteria for PsA Proposed in 1973 Oldest and best-known Simple to use diagnostic criteria Inflammatory arthritis (peripheral arthritis and/or sacroiliitis or spondylitis) Presence of psoriasis Absence of serological tests for rheumatoid factor Classifies patients with PsA into 5 subgroups Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64(Suppl II).
17 MOLL AND WRIGHT CLASSIFICATION SYSTEM 5 subgroups: Polyarticular, symmetric arthritis Oligoarticular and asymmetric Distal interphalangeal joint (DIP) predominant Spondylitis predominant Arthritis mutilans
18 CLASSIFICATION OF PSORIATIC ARTHRITIS (CASPAR) Patient must have inflammatory articular disease (joint, spine, or entheseal) and >3 points Category Description Points Current psoriasis or Personal or family history of psoriasis Nail psoriasis Current psoriasis: skin or plaque disease confirmed by a rheumatologist or dermatologist Family history: in 1 st or 2 nd degree relative Onycholysis, pitting, or hyperkeratosis Negative rheumatoid factor 1 Dactylitis (current or history) Swelling of entire digit 1 Radiographic evidence of periarticular new bone formation Found on x-rays of hand or foot (excludes osteophytes) 2 (current) or 1 (history) 1 1
19 CASE STUDY: CLASSIFICATION
20 CASE STUDY: CLASSIFICATION Kim is a 38 year old white woman you have treated in your practice for five years. Kim has a 3-year history of mild scalp psoriasis but is an otherwise healthy mother of two who works as an attorney. At the end of her most recent annual physical, she mentions she has been experiencing intermittent low back and right sided hip pain with difficulty bending over when picking up her kids or cleaning around the house. Kim notes that the pain began about six months ago without injury and comes and goes without any obvious trigger, although the pain seems to be worse when she gets up in the morning. Kim states that she thinks it is normal wear and tear from years of running and standing long periods in court, but would like to know if there are any athome or OTC remedies she can take when the pain begins. She denies fever, swelling and pain in other joints or worsening of her scalp psoriasis. Clinical case: psoriatic arthritis. American College of Rheumatology.
21 CASE STUDY: CLASSIFICATION Moll and Wright Psoriasis (-) RF Inflammatory arthritis Meets 1 of 5 subgroup types Polyarticular, symmetric arthritis Oligoarticular and asymmetric Distal interphalangeal joint predominant (DIP) Spondylitis predominant Arthritis mutilans CASPAR Inflammatory articular disease Current psoriasis (2) Nail psoriasis (0) Negative rheumatoid factor (1) Dactylitis (0) Radiographic evidence (0)
22 ASSESSMENT OF PSA
23 ASSESSMENT OF PSA Requires consideration of all major disease domains Peripheral arthritis Axial disease Enthesitis Dactylitis Psoriasis Nail disease Impact of disease on quality of life Structural damage Relevant comorbidities
24 PSORIASIS ASSESSMENT (SKIN) General Principles Body surface area (BSA) involvement Palm size = 1% BSA Rule of Tens Handprint = 1% BSA Assessment Methods Psoriasis Area and Severity Index (PASI) Physician Global Assessment (PGA)
25 ACR JOINT COUNT American College of Rheumatology (ACR) uses joint counts in assessment of rheumatoid arthritis Several types of joint count methods: 66/68 Joint Count Ritchie Articular Index Thompson-Kirwan Index 44-Swollen Joint Count 28-Joint Count
26 ACR JOINT COUNT Stekhoven D, et al. Hypothesis-free analysis from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatology. 2017; 36(9):
27 JOINT COUNTS IN PSA ACR Joint Counts originally developed for RA Limitations to use for patients with PsA Modified ACR Count developed for PsA Reproducibility verified by studies Not tested specifically for sensitivity to change over time Miedany Y. Recent developments in management of psoriatic arthritis. Current Rheumatology Reviews. 2005; 1:9-19.
28 DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA) Originally developed for reactive arthritis Validated for use in PsA Assesses 5 variables: Tender and swollen joints Patient pain assessment (PPA) and patient global assessment (PtGA) Serum acute-phase response (c-reactive protein)
29 /user_upload/microsites/ohne_az/ m_cc13/rheuma/templates/dapsa_ ENG.pdf
30 QUALITY OF LIFE ASSESSMENT Important to assess the impact of disease on patient s quality of life Physical function Participation Measure of improvement in these areas with treatment Many different scales to assess Medical Outcomes Study Short Form 36 (SF-36) Arthritis Impact Measurement Scales (AIMS and AIMS2) Psoriatic Arthritis Quality of Life (PsAQoL) Mease PJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 (Suppl III):ii49-ii54.
31 ADDITIONAL ASSESSMENT TOOLS Psoriatic Arthritis Screening and Evaluation (PASE) Psoriasis Epidemiology Screening Tool (PEST) Toronto Psoriatic Arthritis Screening Tool (ToPAS) Early Arthritis for Psoriatic Patients Questionnaire (EARP)
32 PROGRESSION TO SEVERE DISEASE The following factors indicate a higher likelihood of severe disease: 5+ swollen joints Elevated acute-phase reactants High medication use Poor response to initial treatment Radiologic evidence of bone erosion PsA-related disability
33 MINIMAL DISEASE ACTIVITY (MDA) 5 out of 7 Criteria Met = MDA Health Assessment Questionnaire <0.5 Swollen joint count <1 Tender joint count <1 Tender entheseal joints <1 PASI / BSA <1 or < 3 Patient assessment of pain on VAS <15 Patient global activity on VAS <20 Coates LC, Fransen J, Helliwell PS. Ann Rheum Dis Jan; 69(1):
34 PSORIATIC ARTHRITIS GUIDELINES
35 PSORIATIC ARTHRITIS GUIDELINES American College of Rheumatology and National Psoriasis Foundation Clinical Practice Guidelines Currently under peer review Anticipated 2018 release European League Against Rheumatism (EULAR): Recommendations for Management of Psoriatic Arthritis with Pharmacologic Therapies 2015 update Support/Clinical-Practice-Guidelines/Psoriatic-Arthritis
36 GOALS OF TREATMENT Reduction of pain Improvements in the other signs and symptoms of disease (including skin and nail involvement) Optimization of functional capacity and quality of life Inhibition of the progression of joint damage
37 Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Figure reprinted with permission from Oxford University Press.
38 TREATMENT OPTIONS Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Traditional disease-modifying antirheumatic drugs (DMARDs) (oral agents) Biologics PDE-4 Inhibitor JAK Inhibitor Complementary and alternative medicine (CAM)
39 NSAIDS Nonsteroidal Anti-Inflammatory Drugs Available over-the-counter and by prescription Alleviate joint symptoms Examples: Ibuprofen Naproxen sodium Sulindac Indomethacin Etodolac
40 Arachidonic Acid COX-1 COX-2 Cytoprotective prostaglandins (platelet aggregation, GI mucosal integrity, renal function) Inflammatory prostaglandins (pain, inflammation, mitosis, growth)
41 NSAID SELECTIVITY Nonselective COX-1 and COX-2 Inhibitors Preferential COX-2 Inhibitors Aspirin Meloxicam Celecoxib Ibuprofen Diclofenac Ketoprofen Indomethacin Naproxen Etodolac Selective COX-2 Inhibitors
42 Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Figure reprinted with permission from Oxford University Press.
43 NSAID ADVERSE EFFECTS Worsening of psoriatic skin lesions Adverse effects by organ system: Cardiovascular risk Gastrointestinal Renal Central nervous system
44 CORTICOSTEROIDS
45 CORTICOSTEROIDS MOA: Provide relief from pain and stiffness by reducing inflammation Glucocorticoids >PLA >Eicosanoid + PAF synthesis Prostaglandins Leukotrienes The main mediators of pain and inflammation
46 CORTICOSTEROIDS Corticosteroids are available in various formulations Topical: 1 st line treatment for skin psoriasis Oral: not used for skin lesions; conditionally recommended for PsA Injectable: used for mild PsA (minimal joints)
47 Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Figure reprinted with permission from Oxford University Press.
48 CORTICOSTEROID INJECTIONS Periodic intra-articular injections can be used as 1 st line as adjunct to NSAIDs Mild peripheral disease, dactylitis, and enthesitis Never used as monotherapy Sometimes used as bridge therapy while DMARD is instituted or in case of acute flare-ups Administered by a physician Examples include: Prednisone Cortisone Dexamethasone Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League against Rheumatism European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4 12.
49 CORTICOSTEROIDS Provide relief from pain and stiffness by reducing inflammation Long-term use should be avoided due to high risk of adverse effects Psychosis Retention of fluid/edema/hypertension Weight gain Peptic ulcer disease (PUD) Infection Osteoporosis Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League against Rheumatism European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4 12.
50 TRADITIONAL DMARDS Disease-Modifying Anti-Rheumatic Drugs Available by prescription only Induce remission of disease Examples include: Methotrexate Leflunomide Sulfasalazine Cyclosporine Antimalarial drugs
51 METHOTREXATE (MTX) MOA: Competitively inhibits dihydrofolate reductase Dosing: Initial: 2.5-5mg test dose Weekly: mg Folate supplementation Reduces synthesis of folate cofactors Reduces production of nucleic acids responsible for cell division and proliferation 1-5mg/day except on days of MTX Adverse effects: GI (vomiting, diarrhea, stomatitis) Mucosal ulcers Hepatotoxicity Thrombocytopenia Pulmonary toxicity Contraindications: Chronic liver disease Immunocompromised Preexisting blood disorders Pregnant/nursing
52 METHOTREXATE: MONITORING CBC with differential and platelets Baseline 7 to 14 days after initiating therapy or dose increase Every 2 to 4 weeks for first few months Every 1 to 3 months depending on leukocyte count and stability of patient BUN and serum creatinine Baseline and every 2 to 3 months Calculate glomerular filtration rate if at risk for renal dysfunction LFTs Baseline Monthly for first 6 months Every 1 to 2 months Pregnancy test Chest x-ray and pulmonary function test Lexi-Drugs (Methotrexate) Lexicomp Online. Hudson, OH: Lexicomp, Inc. Accessed August 9, 2018.
53 LEFLUNOMIDE Prodrug that is metabolized into a pyrimidine synthesis inhibitor T-cell anti-inflammatory effect in vivo Dosing: 20mg QD Patient response seen within 1 month Jones P, White D. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol. 2010;2:53-71.
54 LEFLUNOMIDE + METHOTREXATE In patients with RA who were resistant to methotrexate, leflunomide therapy may be added Different, but complementary, mechanisms of action Requires careful monitoring of liver function tests
55 LEFLUNOMIDE ADVERSE EFFECTS Diarrhea Hepatotoxicity Anaphylaxis Teratogen (possible carcinogen) Pregnancy-absolute contraindication
56 SULFASALAZINE Prodrug converted to sulfapyridine + 5-aminosalicyclic acid in the colon by enteric bacteria Mechanism of action unknown, but thought to function as an antiinflammatory agent Dose: Initial: 500 mg QD Maintenance: 2-3 g daily in divided doses Patient response seen within a month; may take up to 12 weeks in some patients
57 SULFASALAZINE ADVERSE EFFECTS Nausea and vomiting Hypersensitivity Renal dysfunction Anemia Infertility (male) Photosensitivity May make urine/skin yellow
58 CYCLOSPORINE MOA: suppresses IL-2 and TNF inflammatory actions of T-cells A last resort DMARD Effective for peripheral arthritis, axial involvement, and skin lesions 2 most serious side effects: Nephrotoxicity Hypertension
59 ANTIMALARIAL AGENTS Not FDA-approved for use in PsA May be beneficial to treat joint inflammation due to additional MOA aside from interfering with malarial parasites Inhibition of transportation of neutrophils and chemotaxis of eosinophils Reports of favorable responses have been offset by the worsening of skin disease Efficacy and safety not yet established in PsA Future possibilities: Hydroxychloroquine Chloroquine phosphate Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Annals of the Rheumatic Diseases 2005;64(Suppl II):ii74-ii77.doi: /ard
60 Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Figure reprinted with permission from Oxford University Press.
61 TRADITIONAL DMARDS-PLACE IN THERAPY Traditional DMARDs are indicated for moderate-to-severe disease within multiple domains of psoriatic arthritis Peripheral arthritis (first line) Dactylitis (second line) Typically indicated once a patient has insufficient response to NSAIDs and/or local glucocorticoid injections
62 BIOLOGIC DMARDS TNF-Inhibitors T-cell (T-lymphocyte) blockers Interleukin blockers JAK inhibitors
63 BIOLOGIC DMARDS: TNF-INHIBITORS
64 TNF-ΑLPHA INHIBITORS Etanercept Infliximab Adalimumab Golimumab Certolizumab pegol
65 TNF-ALPHA INHIBITORS MOA: TNF-α is a protein expressed on the surface of macrophages, T- lymphocytes, natural killer cells, smooth muscle cells, and fibroblasts It is a proinflammatory cytokine implicated in the pathogenesis of many diseases, such as rheumatoid arthritis, inflammatory bowel disease, and ankylosing spondylitis Reduction of TNF-α leads to reduced chronic inflammatory responses in these diseases Tauseef A, et al. Clinical use of anti-tnf therapy and increased risk of infections. Drug Health Patient Saf. 2013;5:79-99.
66 TNF-INHIBITORS: GENERAL PRINCIPLES Contraindicated in patients with active, serious infections PPD testing should be performed on all patients Do not give live vaccines Do not use in patients with multiple sclerosis (MS) or demyelinating diseases Caution in patients with heart failure Screening for hepatitis B infection when appropriate
67 ETANERCEPT MOA: binds to TNF-α and blocks interaction with cell surface receptors Dose: 50mg subq once weekly Off-label: 25mg twice weekly Biosimilar: Etanercept-szzs
68 ETANERCEPT ADMINISTRATION
69 INFLIXIMAB MOA: binds to both the soluble and transmembrane TNF-α molecules, thereby neutralizing the effects of TNF-α Dose: IV 5mg/kg at 0, 2, and 6 weeks, followed by 3mg/kg every 8 weeks thereafter Often given in combination with methotrexate Biosimilars: Infliximab-dyyb Infliximab-qbtx Infliximab-abda
70 ADALIMUMAB MOA: binds to TNF-α Interferes with binding to TNF-α receptor sites and subsequently cytokinedriven inflammatory processes Dosing: 40mg subq every other week May continue methotrexate, other nonbiologic DMARDs, corticosteroids, NSAIDs, and/or analgesics Biosimilars: Adalimumab-atto Adalimumab-adbm
71 ADALIMUMAB: ADMINISTRATION e.com/pdf/humirape n_pil.pdf
72 GOLIMUMAB MOA: binds to TNF-α, thus interfering with endogenous TNF-α activity Dose: IV Golimumab: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter SubQ Golimumab: 50mg once a month Used alone or in combination with methotrexate or other nonbiologic DMARDs
73 CERTOLIZUMAB PEGOL MOA: binds to and selectively inhibits TNF-α activity Dose: SubQ 400mg (given as 2 injections of 200mg each) Repeat dose 2 and 4 weeks after initial dose Maintenance: 200mg every 2 weeks or 400mg every 4 weeks
74 BIOLOGIC DMARDS: T-CELL BLOCKERS Abatacept
75 ABATACEPT MOA: inhibits T-cell (T-lymphocyte) activation by binding to antigen presenting cells (APC), thus blocking the interaction between the two Activated T-lymphocytes are found in the synovium Without Abatacept With Abatacept Illustrating drug binding to CD80/86 and blocking CD28 from binding
76 ABATACEPT Dose: IV: dosed based on body weight; initial infusion followed by repeat infusions at 2 and 4 weeks, then every 4 weeks thereafter SubQ: 125mg once weekly Given alone or in combination with nonbiologic DMARDs
77 BIOLOGIC DMARDS: INTERLEUKIN BLOCKERS
78 INTERLEUKIN BLOCKERS Ustekinumab Secukinumab Ixekizumab
79 INTERLEUKIN BLOCKERS
80 USTEKINUMAB MOA: inhibits IL-12 and IL-23 Dose: 45mg subq at 0 and 4 weeks, then every 12 weeks thereafter Similar to TNF-inhibitors, serious infections remain a concern
81 USTEKINUMAB: MONITORING/ADVERSE EFFECTS Development of malignancies (1.3%) Monitor at-risk patients for non-melanoma skin cancer Other adverse effects include injection site reactions, headache and fatigue Avoid live vaccines
82 SECUKINUMAB MOA: selectively binds to IL-17 Dose: With loading dose: 150mg subq at weeks 0, 1, 2, 3, and 4 followed by 150mg every 4 weeks Without loading dose: 150mg subq every 4 weeks
83 IXEKIZUMAB MOA: selectively binds to IL-17A Dose: 160mg subq given once, followed by 80mg every 4 weeks *for patients with coexisting moderate-to-severe plaque psoriasis, the dosing schedule for plaque psoriasis is used
84 PDE-4 INHIBITOR
85 APREMILAST Phosphodiesterase 4 (PDE-4) inhibitor MOA: PDE-4 regulates the conversion of camp AMP Inhibition of PDE-4 allows for increased levels of camp This results in decreased production of pro-inflammatory cytokines and increased production of anti-inflammatory mediators Targeted synthetic DMARD
86 APREMILAST Used in the treatment of peripheral disease as well as dactylitis and enthesitis Limited to patients who have failed NSAIDs, corticosteroids, and both the traditional and biologic DMARDs Dose: 30mg BID
87 APREMILAST ADVERSE EFFECTS Depression Weight loss Diarrhea Headache
88 Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rheumatology 2016; 68(5): Figure reprinted with permission from Oxford University Press.
89 JAK INHIBITOR
90 TOFACITINIB MOA: inhibits JAK enzymes Inhibition of these enzymes affects the signaling of multiple cytokines involved in inflammation Dose: Immediate release: 5mg BID Extended release: 11mg QD May use in combination with nonbiologic DMARDs
91 TOFACITINIB ADVERSE EFFECTS Serious infections Herpes zoster (shingles) Infections in patients with diabetes Cancer and immune system problems Tears in stomach or intestines
92 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM)
93 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) The National Center for Complementary and Alternative Medicine (NCCAM) and The National Center for Health Statistics (part of the CDC) show that more than 1/3 of Americans use complementary and alternative medicine Evidence support for CAM use in psoriatic arthritis is anecdotal Options: Diet and Nutrition Herbal Remedies Mind/Body Therapies Alternative Therapies Exercise (including Yoga & Tai Chi) Complementary and Alternative Therapies. National Psoriasis Foundation Accessed August 14, 2018.
94 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) Diet and Nutrition Reduce alcohol, gluten, and nightshades Add fish oil, vegetables, and vitamin D Special diets: Pagano Vegan Paleo Herbal Remedies Aloe Vera Apple Cider Vinegar Capsaicin Tea Tree Oil Turmeric Mind/Body Therapies Aromatherapy Chamomile, Tea Tree, Rose, Lavender Meditation Mindfulness Spa therapy Alternative Therapies Acupuncture Acupressure Massage Exercise Yoga Tai Chi
95 SUMMARY Psoriatic arthritis is a chronic, progressive type of inflammatory arthritis Patients with psoriatic skin disease should be assessed for symptoms of psoriatic arthritis Symptoms may include pain, stiffness and tenderness in the joints, as well as dactylitis, enthesitis, and nail changes Treatment options include NSAIDs, corticosteroids, oral DMARDs, biologics, PDE-4 inhibitors, and JAK inhibitors
96 THANK YOU! Jamie L. McConaha, PharmD
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationClinical Practice Guideline. Psoriatic Arthritis (PsA) Version
Clinical Practice Guideline Psoriatic Arthritis (PsA) Version 1.1.2016 August 2016 Table of Contents Introduction...5 Diagnosis...6 Patient Assessment... 7 Management of Patients with PsA...8 Peripheral
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationCLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH
CLOSER LOOK AT SpA Dr. Mohamed Bedaiwi Consultant Rheumatologist Rheumatology Unit - KKUH Closer look at SpA I. Categories II. SIGN & SYMPTOMS III. X-RAY IV. MRI V. MANAGMENT Spondyloarthritis (SpA)
More information2018 ReachMD Page 1 of 10
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationA Patient s Guide to Psoriatic Arthritis
A Patient s Guide to Psoriatic Arthritis Glendale Adventist Medical Center 1509 Wilson Terrace Glendale, CA 91206 Phone: (818) 409-8000 DISCLAIMER: The information in this booklet is compiled from a variety
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationEffective management of arthritis. Gail Dolan Victoria ACH Liz McIvor Stobhill ACH
Effective management of arthritis Gail Dolan Victoria ACH Liz McIvor Stobhill ACH Role Types of arthritis Drugs Self Management Role Of CNS Advanced level nurses offering specialist care in a specific
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationPharmacy Management Drug Policy
SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationSubject: Remicade (Page 1 of 5)
Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More information5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue
5//18 Disclosures Management of Psoriatic Arthritis Alexis Ogdie, MD MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Psoriatic Arthritis Clinic Division of Rheumatology Center for
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationProper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D.
167 Update on Treatment of Psoriatic Arthritis Philip Mease, M.D. Abstract Some of this past year s key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper.
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationCimzia (certolizumab pegol)
DRUG POLICY BENEFIT APPLICATION Cimzia (certolizumab pegol) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Commercial Medical Benefit Drug Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHA031 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE...
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationHumira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018
Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including
More informationInfliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)
Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationSwitching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Drugs R D (2017) 17:509 522 DOI 10.1007/s40268-017-0215-7 REVIEW ARTICLE Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence Luisa Costa 1 Carlo Perricone 2 Maria Sole
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationDMARD s in Clinical Practice
DMARD s in Clinical Practice Professor Md. Mahabubul Islam Majumder Professor & Head, Department of Medicine Comilla Medical College, Comilla Bangladesh Disease-modifying antirheumatic drugs (DMARDs) A
More informationIdentification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care
Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Joy Schechtman D.O. Professor Midwestern University 64C-1876207 Disclosures None 3 64C-1876207
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationConcept of Spondyloarthritis (SpA)
Concept of Spondyloarthritis (SpA) Spondyloarthritis: Characteristic Parameters Used for Diagnosis I Symptoms Inflammatory back pain Imaging Lab ESR/CRP Patient s history Good response to NSAIDs Spondyloarthritis-Characteristic
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationJurnal Medical Aradean (Arad Medical Journal) Vol. XVIII, issue 1, 2015, pp Vasile Goldis University Press (www.jmedar.
Vol. XVIII, issue 1, 15, pp. 4-45 15 Vasile Goldis University Press (www.jmedar.ro) DEMOGRAPHIC AND CLINICAL PARAMETERS EVALUATION FOR PATIRNTS WITH PSORIATIC VERSUS RHEUMATOID ARTHRITIS Camelia Ciacli
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationGrigorios T. Sakellariou, 1 Athanasios D. Anastasilakis, 2 Ilias Bisbinas, 3 Anastasios Gketsos, 4 and Charalampos Berberidis 1. 1.
ISRN Rheumatology Volume 2013, Article ID 907085, 4 pages http://dx.doi.org/10.1155/2013/907085 Clinical Study Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationDr Tracey Kain. Associate Professor Ed Gane
Associate Professor Ed Gane New Zealand Liver Transplant Unit Auckland Dr Tracey Kain Consultant Rheumatologist Grace Orthopaedic Centre Tauranga Hospital Tauranga 7:00-7:55 Abbvie Breakfast Session 1.
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationEARLY INFLAMMATORY ARTHRITIS. Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital
EARLY INFLAMMATORY ARTHRITIS Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital EIA: Introduction National priority Preventable cause of disability Very common condition High
More information